• #LGM Pharma is a Ganirelix Acetate CAS# 129311-55-3 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 129311-55-3
  • AHFC code:
  • Synonyms: Antagon, D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N(sup 6)-((ethylamino)(ethylimino)methyl)-D-lysyl-L-leucyl-N(sup 6)-((ethylamino)(ethylimino)methyl)-L-lysyl-L-prolyl-, diacetate (salt), Ganirelix acetate, Ganirelix acetate injection, N-Acetyl-3-(2-naphthyl)-D-alanyl-p-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N(sup 6)-(N,N'-diethylamidino)-D-lysyl-L-leucyl-N(sup 6)-(N,N'-diethylamidino)-L-lysyl-L-prolyl-D-alaninamide diacetate (salt), RS-26306, UNII-56U7906FQW
  • ATC Code: H01CC01
  • Chemical Formula: C80-H113-Cl-N18-O13.2C2-H4-O2
  • Molecular Weight: 1690.4419
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB06785
  • SMILES: CCNC(=NCCCC[C,H](C(=O)N[C,,H](CC(C)C)C(=O)N[C,,H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C,H]1C(=O)N[C,H](C)C(=O)N)NC(=O)[C,,H](Cc2ccc(cc2)O)NC(=O)[C,,H](CO)NC(=O)[C,H](Cc3cccnc3)NC(=O)[C,H](Cc4ccc(cc4)Cl)NC(=O)C(Cc5ccc6ccccc6c5)NC(=O)C)NCC.CC(=O)O.CC(=O)O
  • InChl:
  • PubChem:
  • IUPAC:

Additional Details

For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Mode of Action:
Ganirelix acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by ganirelix is more pronounced than that of FSH. An initial release of endogenous gonadotropins has not been detected with ganirelix, which is consistent with an antagonist effect. Upon discontinuation of ganirelix, pituitary LH and FSH levels are fully recovered within 48 hours.
Following single-dose intravenous administration of radiolabeled ganirelix acetate to healthy female volunteers, ganirelix Acetate is the major compound present in the plasma (50–70% of total radioactivity in the plasma) up to 4 hours and urine (17.1–18.4% of administered dose) up to 24 hours. Ganirelix Acetate is not found in the feces. The 1–4 peptide and 1–6 peptide of Ganirelix Acetate are the primary metabolites observed in the feces.
General Reference:
Oberye J, Mannaerts B, Huisman J, Timmer C: Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran) administration by Medi-Jector compared to conventional needle injections. Hum Reprod. 2000 Feb;15(2):245-9. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials